XLO biotech catalysts & pipeline

XILIO THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

efarindodekin alfa — Full data

H1 2027

Xilio is evaluating efarindodekin alfa as a monotherapy in an ongoing Phase 2 clinical trial in patients with advanced solid tumors and expects to deliver an option data package to Gilead Sciences, Inc. (Gilead) in the first half of 2027.

Source filing

masked T cell engagers — IND submission

in 2027

Xilio plans to advance these masked T cell engager programs into IND-enabling studies and submit IND applications for each of these programs in 2027.

Source filing

PSMA+STEAP1 SEECR — IND submission

2027

PSMA+STEAP1 SEECR: IND submission (2027)

Source filing

CLDN18.2 — IND submission

H2 2027

Xilio plans to submit INDs for its CLDN18.2 and PSMA+STEAP1 programs in the second half of 2027.

Source filing

PSMA and STEAP1 — IND submission

H2 2027

Xilio plans to submit INDs for its CLDN18.2 and PSMA+STEAP1 programs in the second half of 2027.

Source filing

XTX501 — Initial data

H2 2027

Xilio plans to report initial Phase 1 data in patients with metastatic NSCLC in the second half of 2027.

Source filing

Explore the free biotech catalyst calendar